Detalhe da pesquisa
1.
Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways.
Cancer Immunol Immunother
; 64(1): 61-73, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25287778
2.
Alterations of NK Cell Phenotype in the Disease Course of Multiple Myeloma.
Cancers (Basel)
; 13(2)2021 Jan 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33435153
3.
A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma.
Clin Cancer Res
; 26(2): 344-353, 2020 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31672767
4.
Enhanced SLAMF7 Homotypic Interactions by Elotuzumab Improves NK Cell Killing of Multiple Myeloma.
Cancer Immunol Res
; 7(10): 1633-1646, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31431433
5.
Pharmacologic inhibition of site 1 protease activity inhibits sterol regulatory element-binding protein processing and reduces lipogenic enzyme gene expression and lipid synthesis in cultured cells and experimental animals.
J Pharmacol Exp Ther
; 326(3): 801-8, 2008 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-18577702
6.
Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab.
Mol Cancer Ther
; 17(7): 1454-1463, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29654064
7.
The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and -independent mechanisms.
Oncoimmunology
; 6(9): e1339853, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28932638
8.
PD-1 blockade enhances elotuzumab efficacy in mouse tumor models.
Blood Adv
; 1(12): 753-765, 2017 May 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29296719
9.
The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications.
Clin Cancer Res
; 23(15): 3980-3993, 2017 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28428191
10.
Development and Validation of Electrochemiluminescence Assays to Measure Free and Total sSLAMF7 in Human Serum in the Absence and Presence of Elotuzumab.
AAPS J
; 18(4): 989-99, 2016 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27116021
11.
Discovery of PF-04449913, a Potent and Orally Bioavailable Inhibitor of Smoothened.
ACS Med Chem Lett
; 3(2): 106-11, 2012 Feb 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-24900436
12.
Aminopyrrolidineamide inhibitors of site-1 protease.
Bioorg Med Chem Lett
; 17(16): 4411-4, 2007 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-17583500